logo
Twitter
Discord
Email
logo
10x Genomics, Inc.

10x Genomics, Inc.

NASDAQ•TXG
CEO: Dr. Serge Saxonov Ph.D.
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Listing Date: 2019-09-12
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Contact Information
6230 Stoneridge Mall Road, Pleasanton, CA, 94588-3260, United States
925-401-7300
www.10xgenomics.com
Market Cap
$2.24B
P/E (TTM)
-29.8
56
Dividend Yield
--
52W High
$20.34
52W Low
$6.78
52W Range
84%
Rank66Top 89.6%
1.9
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 1.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2017-2024

Financial Dashboard

Q3 2025 Data

Revenue

$149.00M-1.75%
4-Quarter Trend

EPS

-$0.22-26.67%
4-Quarter Trend

FCF

$42.53M+139.56%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Operating Expenses Decline 10% Total operating expenses dropped 10% to $132.549 M, aided by $49.9 M settlement gain recognized in the quarter.
Net Loss Narrows Significantly Quarterly net loss improved to $(27.472) M versus $(35.753) M last year, despite overall revenue contraction.
Cash Position Remains Robust Ended period with $432.709 M in cash, cash equivalents, and restricted cash available for operations and investment.

Risk Factors

Quarterly Revenue Declines Total revenue decreased 2% to $149.002 M for the quarter, driven by instrument sales contraction across segments.
Gross Margin Compression Noted Gross margin compressed to 67% from 70% due to higher manufacturing costs and inventory write-downs impacting profitability.
Continued Operating Losses Expected Management expects to continue incurring operating losses for the foreseeable future impacting overall cash burn rate.
Pending Litigation Exposure Active patent litigation against Parse, Curio, and Illumina presents ongoing legal and financial uncertainties for the Company.

Outlook

Expense Reduction Trend Continues Expect operating expenses to trend lower throughout the remainder of 2025 following recent workforce and cost reductions.
Scale Acquisition Payment Due $20.0 M payment expected in Q1 2026 related to the technology transfer completion for the Scale asset acquisition.
Sequential Revenue Increase Expected Management anticipates revenues will moderately increase sequentially during the fourth quarter of 2025, driven by services.
Capital Expenditure Planning Anticipate aggregate capital expenditures between $15 M and $20 M over the next twelve months period for growth.

Peer Comparison

Revenue (TTM)

Teladoc Health, Inc.TDOC
$2.53B
-2.4%
Clover Health Investments, Corp.CLOV
$1.77B
+14.8%
Guardian Pharmacy Services, Inc.GRDN
$1.39B
+18.7%

Gross Margin (Latest Quarter)

GoodRx Holdings, Inc.GDRX
93.2%
-0.9pp
Phreesia, Inc.PHR
85.2%
+24.6pp
Teladoc Health, Inc.TDOC
70.1%
-1.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TXG$2.24B-29.8-10.3%8.5%
ESTA$2.05B-25.2-253.8%0.9%
GRDN$1.86B45.324.7%8.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-3.3%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 7, 2025|
    Revenue: $149.00M-1.7%
    |
    EPS: $-0.22-26.7%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 8, 2025|
    Revenue: $172.91M+12.9%
    |
    EPS: $0.28-187.5%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 9, 2025|
    Revenue: $154.88M+9.8%
    |
    EPS: $-0.28-44.0%
    Beat
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 13, 2025|
    Revenue: $610.79M-1.3%
    |
    EPS: $-1.52+30.3%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 29, 2024|
    Revenue: $151.65M-1.3%
    |
    EPS: $-0.30-62.0%
    Meet
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $153.10M+4.3%
    |
    EPS: $-0.32-39.6%
    Beat
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: Apr 30, 2024|
    Revenue: $141.01M+5.0%
    |
    EPS: $-0.50+13.6%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 15, 2024|
    Revenue: $618.73M+19.8%
    |
    EPS: $-2.18-49.3%
    Miss